Di Zhe Pharmaceutical (688192.SH): The net loss narrowed to 857 million yuan in 2024, while revenue surged by 294.79% to 360 million yuan.

Di Zhe Pharmaceutical (688192.SH) released its 2024 annual performance report announcement, achieving a total operating income of 360 million yuan during the reporting period, a year-on-year increase of 294.79%; a net loss attributable to the owners of the parent company of 857 million yuan, a decrease in losses compared to the previous year; a net loss attributable to the owners of the parent company after deducting non-recurring gains and losses of 910 million yuan, a decrease in losses compared to the previous year; basic loss per share of 2.07 yuan. As a global R&D company for innovative drugs, continuous R&D investment is a key support for the company's high-quality development, making continuous R&D investment in innovative drugs one of the main factors affecting the company's financial condition. This reporting period is the first complete accounting year in which the company achieved product sales revenue, totaling 360.39 million yuan; as products are gradually launched, product sales revenue and sales promotion expenses will become the main factors affecting the company's financial condition.